



26<sup>th</sup> ASIA-PACIFIC PROSTATE CANCER CONFERENCE

# APCC26

Melbourne Convention & Exhibition Centre, Australia | AUGUST 13-15

Together In Discovery & Care



## THE ROLE OF METASTASIS DIRECTED THERAPY IN OLIGOMETASTATIC PROSTATE CANCER: EVIDENCE, INTEGRATION INTO PRACTICE AND FUTURE DIRECTIONS



**THURSDAY**  
**13 August, 2026**  
0830 - 1330

**As the treatment landscape for prostate cancer continues to evolve, metastasis directed therapy has emerged as a compelling strategy for managing oligometastatic disease.**

This workshop, featuring lectures and case-based debates, will explore the biological rationale, advanced imaging techniques, and clinical trial data shaping the role of metastasis directed therapy in contemporary prostate cancer care.

Attendees will leave with a nuanced, evidence-informed understanding of when, how, and for whom metastasis directed therapy can offer the greatest benefit.

Whether you're a radiation oncologist, urologist, medical oncologist, or imaging specialist, this workshop delivers cutting-edge insights into one of the most promising frontiers in prostate cancer management. Come learn about these aspects, find resources for your location of practice and share your experiences.

<b>0830-0845</b>	<b>Welcome</b>
0845-0900	<b>Biological rationale and evidence for metastasis directed therapy</b> A/Prof Marlon Perera, Peter MacCallum Cancer Centre, Melbourne
0900-0915	<b>Optimising patient selection – next generation imaging</b> Prof Rodney Hicks, MTIC, Melbourne
0915-0930	<b>PSMA based radioguided surgery in primary and recurrent prostate cancer</b> A/Prof Giorgio Gandaglia, Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Italy
0930-0945	<b>Rationale for involved site SBRT: Enhanced Intermittent ADT in nodal oligorecurrent prostate cancer</b> Prof Sean Collins, University of South Florida, United States
0945-1000	<b>Real world clinical outcomes – Australian experience</b> Dr Jeremy de Leon, GenesisCare, Sydney
1000-1015	<b>Oligorecurrent nodal prostate cancer metastases: SBRT versus elective whole-pelvic radiotherapy</b>
1015-1030	<b>Question &amp; Answer</b>
<b>1030 - 1100</b>	<b>Morning Tea</b>
1100-1115	<b>The role of systemic therapy in oligometastatic hormone sensitive prostate cancer in the metastasis directed therapy era</b> A/Prof David Pook, Cabrini Health, Melbourne
1115-1130	<b>Metastasis directed therapy in mCRPC</b>
1130-1145	<b>Radioligand therapy as metastasis directed therapy</b> Prof Oliver Sartor, East Jefferson General Hospital (EJGH) Cancer Center, United States
1145-1245	<b>Case presentations and expert panel Q&amp;A</b> Panel
<b>1245 - 1330</b>	<b>Lunch</b>



### FACULTY

**Professor Sean Collins**  
University of South Florida,  
United States



**A/Professor Giorgio Gandaglia**  
Vita-Salute San Raffaele University  
& IRCCS San Raffaele Hospital, Italy



**Professor Oliver Sartor**  
East Jefferson General Hospital  
(EJGH) Cancer Center, United States

### WORKSHOP CHAIRS

Dr Phil Dundee & Dr Mario Guerrieri

[Program correct at time of publication]

### FIND OUT MORE

Scan the QR code to learn more about the APCC26 workshops.



**For a 10% discount use code UROLOGY10**

Proudly sponsored by

